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ABSTRACT
Biosensors are heterogenous devices, incorporating biological struc-
tures combined with electronics, optical or other readout systems.
They have been developed for detecting different biomolecules and/or
pathogens and represent a key technology for advanced and point-
of-care diagnostics as well as patient monitoring. In this paper we
present a systematic classification of biosensors described in litera-
ture, particularly focusing on nanotechnology-based sensing. Then,
we present our approach to develop electrochemical biosensors for
measuring metabolites and anticancer drugs, based on a platform
for multiple target detection. This platform is modular and achieves
a clear separation between the chemical and the electrical compo-
nents, thus easing design and manufacturing. It shows superior per-
formance thanks to the excellent properties of electron transfer and
selectivity showed by enzymes immobilized on carbon nanotubes.
Categories and Subject Descriptors
J.3 [Life and Medical Sciences]: Health
General Terms
Measurement
Keywords
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1. INTRODUCTION
The integration of biosensors with electrical data acquisition chains
and information systems opens new opportunities for health man-
agement. In particular integrated biosensors are key elements for
advanced diagnostics, including portable and disposable devices,
and for monitoring metabolites and/or drug concentrations, thus en-
abling (possibly remote) treatment of chronic patients. Drug mon-
itoring in human fluids is important to increase the effectiveness of
therapies, and specifically in the case of personalized treatment. In-
deed, standard drug therapies are based on randomized clinical tri-
als, and treatments are chosen according to the best mean efficacy,
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with improvements in the 20 to 50% patients, while the rest may not
completely benefit from the assigned treatments [10]. For all these
reasons, the development of an integrated platform to monitor the
drug metabolism and the concentration of endogenous compounds
in physiological fluids is highly requested. Optimized treatments
and follow-up therapies can be easily tuned by using point-of-care
devices, which represent a potent and innovative tool for personal-
ized medicine.
Biosensors have been developed for diverse biomolecule and path-
ogen detection. Disposable electrodes are by far one of the most
popular strategy coupled with electronics to develop point-of-care
devices. However, system miniaturization becomes highly impor-
tant and conventional approaches, like disposable electrodes, are a
bottleneck for decreasing the size of the system. A potent approach
to address this limitation is the integration of the biological layer
with the electronic portion of the system. A benefit of integration is
better performance with respect to signal-to-noise ratio, especially
favorable when dealing with biological signals that are typically
weak and noisy. High-density arrays of biosensors and multiple
detection can be achieved by reducing the sensor area with micro-
fabrication techniques. Finally, system miniaturization increases
also sensor response and requires small samples.
System integration is a key issue for self contained biosensors.
Power source, transducer circuitry, control unit, wireless commu-
nication are some of the blocks that can be potentially used in
biosensing systems. However, the integration of all units may not
be a satisfactory solution. Scaling trends for the analog circuit,
the digital unit, and the biosensor itself are different, and so het-
erogeneous technologies may be required [17]. A platform-based
design style using heterogeneous components and compositional
rules eases the design process and reduces the non-recurring engi-
neering (NRE) costs of biosensing systems, thus enabling the in-
troduction of new approaches in the medical arena.
In this paper we present a strategy to develop the sensing block of
a biosensor for the detection of endogenous compounds and anti-
cancer drugs, and we compare its performance with the state-of-
the-art devices. Before presenting the comparative results, we give
an overview of the biosensors used in clinical practice, with partic-
ular emphasis on those suitable for integration.
2. CLASSIFICATION
Biosensors are a subgroup belonging to the wide family of chem-
ical sensors. Biosensors may be classified in different ways. IU-
PAC recommends their classification according to the biological
recognition mechanism or the transduction principles [48]. Here-
under, we want to propose an essential classification of biosensors
that have been proposed in literature during the last decade.
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2.1 Targets
The development of a biosensor is strictly connected to the target
we want to detect. In clinical applications there are lots of analytes
which are interesting to follow. DNA is one of the most important
targets that have been studied during the last decades. Applications
range from medical diagnosis and genome sequencing to food, pol-
lution, and environmental analysis [6]. There are several methods
to detect DNA: the most widely used is typically based on microar-
ray technique, which consists on nucleic acid hybridization and op-
tical readout [35]. Another technique quite popular involves elec-
trical DNA biosensors, based on capacitance measurements [45].
Many researches have been focusing for long time on the detec-
tion of molecules, too. The most studied metabolite over the last
fifty years is by far glucose, which lends to point-of-care device
development and self-management for chronic diseases. Glucose
biosensors are generally based on electrochemical principles, with
a disposable sensing element and a permanent readout device [30].
However, there are other interesting molecules to detect for clini-
cal interest. Over the last two decades there have been proposed
biosensors for lactate [31], cholesterol [43], glutamate [38], creati-
nine[21], etc.
Biomarkers are another large family of biomolecules arising in-
terest, since they are able to point out if a biological process, a
disease, or a response to a therapeutic intervention is in progress.
Currently, the most popular are the cancer biomarkers, including
proteins, peptides, and tumor-related metabolites. One outstanding
example is the prostate specific antigen (PSA) detection, related to
prostate cancer [58], and the carcinoma antigen 125 (CA-125), re-
lated to ovarian cancer [47]. Autoimmune diseases present also dis-
tinctive biomarkers, typically antibodies or auto-antibodies. Sur-
face plasmon resonance (SPR) has showed promising results for
the detection of such biomarkers [11]. Biosensors are also promis-
ing tools for widespread and cheap screening of infectious diseases
by detecting the RNA sequence of virus (for example dengue fever
virus) or hepatitis B antigen. Recent works have presented encour-
aging results for protein detection to achieve the diagnosis of acute
myocardial infarction and presence of coronary plaque [11].
Drugs are a further big category of molecules that can be sensed
by using biosensors. Their monitoring in patient blood can reveal
drug absorption, so that drug supply can be optimized according
to the individual, enhancing the therapeutic efficacy. Some exam-
ples are detectors for paracetamol (analgesic and antipyretic), theo-
phylline (used as therapy for respiratory diseases), chlorpromazine
(antipsychotic), salicylate (antimicrobial agent) [53]. Multi-panel
drug biosensors were also proposed for the detection of drugs by
using cytochrome P450 in different isoforms. Benzphetamine (used
in anti-obesity treatments), cyclophosphamide (used in anti-cancer
therapy), Dextromethorphan (cough suppressant), Naproxen and
Flurbiprofen (anti-inflammatory compounds) were detected with
an electrochemical-based biosensor [9].
2.2 Sensing element
The sensing element is strictly related to the target. Biologi-
cal systems represent the most selective element and they typically
confer specificity to the biosensor. Several biosensors are based on
enzymes. They are complex macromolecules, largely formed by
protein structure, which are able to catalyze a chemical reaction.
Generally, the chemical reaction is then transduced in a signal that
can be measured and correlated to analyte quantity. The enzymes
bind the analyte next to the active site. Enzymes needs a cofactor
to work, which is bound to the protein itself. The cofactor is the
part of the enzyme typically involved in the oxidation or reduction
reaction [44].
Antibodies are another common sensing element. They are able
to specifically bind the corresponding antigen, but they do not pro-
mote or catalyze any chemical reaction. The antigen, i.e. the target,
can be a molecule or a cell (for example a bacteria) [11]. ELISA
(Enzyme-Linked ImmunoSorbant Assay) is maybe the most pop-
ular analytical assay based on the complex antibody-antigen. An
enzyme can be coupled to the antibody as transducer to promote a
colorimetric reaction, for example, even if the sensing element re-
mains the antibody [25].
DNA biosensors are primarily based on nucleic acids as sensing
element. The specificity is conferred by the base-pairing and the
strand of nucleic acids can detect genetic diseases, viral infections,
and cancer [12]. The strands are often labeled with radioactive or
fluorescent compounds, as well as enzymes or electroactive species.
The transduction mechanisms, then, is strictly correlated to the
used label.
The last category of sensing elements is represented by receptors,
which are basically cell-membrane proteins. The detected signal
is typically electrical, since a charge-flow is measured through an
ion-channel [46]. Drugs are mostly the target, even if there are
still evident problems to incorporate such receptors onto biosensors
[34].
2.3 Transduction mechanism
The transduction mechanism is another big section for a detailed
classification. The purpose of the present work is not to give a de-
tailed description of all the mechanisms used for biosensing, but
we want to present an exhaustive overview on the main techniques.
Optical biosensors are typically enzyme-based, since the trans-
duction mechanism is a chemical reaction producing changes in
spectroscopic or spectrophotometric properties. Another strategy
to perform the detection is by labeling secondary antibodies and
DNA strands with fluorescent agents to confer the optical readout
[20]. Surface plasmon resonance-based biosensors belong to the
family of optical sensing and they have increasingly arisen inter-
est in biosensing applications during the last years. This technique
consists of the excitation of the interface between a metal and a di-
electric by using light waves. If the excitation frequency matches
the oscillation frequency of surface charge density, electromagnetic
waves propagate along the interface, called surface plasmons. The
dielectric medium can be functionalized with biological elements:
as soon as the dielectric changes (because the target molecules bind
the receptor), there is also a change in the refractive index [56].
Metal layer is mainly functionalized with antibody for the detec-
tion of antigens and hormones [11].
Piezoelectric biosensors typically detect mass variation and they
are commonly known as quartz crystal microbalance (QCM). The
quartz disk, or the microcantilever for nanoscale sensors, oscillate
because of the application of an alternating electric field. The reso-
nance frequency depends also on system mass. If the surface of the
quartz is coated with sensing elements, once the sensing element
binds the target, the mass of the system varies and shifts the reso-
nance frequency. Such biosensors have been reported for DNA and
pathogens detection and for immunoassays [13].
Surface modification with sensing elements can result in mass vari-
ation, as in the case of piezoelectric biosensors, but it can also result
in the variation of the electrical properties of the surface. If the sur-
face is an electrode, it is possible to quantify such electrical change
by measuring the variation of impedance. Two sub-groups belong
to the family of impedimetric biosensors. Capacitive biosensors are
sensitive to capacitance variation: DNA detectors and immunosen-
sor for tumor biomarkers are often developed according to these
principles [50]. The Faradic impedimetric biosensors foresee to
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couple the antibody with a redox probe: the measured property is
the charge transfer resistance [37].
The last category is represented by the electrochemical biosen-
sors, which are by far the most reported devices in literature. It
is possible to distinguish three sub-groups based on electrochemi-
cal sensing. The catalyzed reaction promoted by the enzyme can
result in a variation of the electrode potential, while no current
flows. Such technique is call potentiometric. Ion-selective sensors
belong to that family. Potentiometric biosensors have been devel-
oped for urea detection in blood, creatinine in biological fluids and
immunosensor assays [23]. Ion charge or Field-Effect-Transistors
(FET) are another category of transduction mechanisms where the
ion charge variation is monitored. Conventional FET can be mod-
ified for biosensing purposes by functionalizing the gate terminal
with probes, for example. The binding between probes and targets
results in a variation of electric charges at the gate terminal [24].
The functionalization can be applied also to the channel, especially
when it is replaced by nanostructures, as nanowires or nanotubes
(as discussed in Section 2.4). In this case the binding mechanism is
transduced in a conductivity variation of the channel [22]. Finally,
there are the amperometric biosensors, where current variation is
monitored as result of the redox reaction promoted by the enzyme
with the target. Amperometric biosensors have had great success
in the market, because they can be produced quite easily and inex-
pensively, and they lend to be integrated in portable devices. Since
their development is quite inexpensive, the sensing element (en-
zyme and electrodes) can be disposable, guaranteing uncontami-
nated and safe self-measurements. Amperometric biosensors have
been developed for many applications: metabolite (especially glu-
cose) and drug monitoring are by far the most common [53].
2.4 Nanotechnology-based biosensors
According to many authors [8], [15], the new frontier of biosens-
ing is nanomaterial employment. Nanomaterials exhibit many in-
teresting properties for biosensing, including dimensions compara-
ble with sensing elements, high electron transfer rate [51], consid-
erable electronic emission [28], and high surface area [2], due to
their 3-D structure.
Nanoparticles (NP) are typically metallic, showing interesting elec-
trical and magnetic properties for biosensing applications. NP ap-
plied in the biosensing field are often made of gold, because of the
numerous ways to modify Au surfaces to obtain high affinity with
biomolecules. Silver and platinum are other two reported metals
used for NP synthesis with similar behavior. They have presented
proper optical properties to be used in biosensing, but also interest-
ing electrical features, as high sensitivity in voltammetry and im-
proved limit of detection in potentiometric techniques [36]. Quan-
tum dots are semiconductor crystals whose size is within 10 nm.
Quantum confinement confers different properties to quantum dots
with respect to larger particles. In fact, they have remarkable op-
tical properties, suitable to be used as labels for sensing elements
[27]. Core shell are a subfamily of NP, with a metallic core and an
organic or inorganic shell, to improve biocompatibility and reduce
particle aggregation [2].
With the improvement of micro and nanofabrication techniques,
nanowires (NW) have been arising more interest in biomedical ap-
plications, since they can interact with biomolecules at the nanoscale.
They can be metallic or semiconductor, according to the transduc-
tion mechanism. NW are often employed in conductive measure-
ments, when functionalized with proteins, enzymes or antibodies,
or field-effect-transistors, as discussed previously in Section 2.3
[39].
Finally, carbon nanotubes (CNT) have shown to possess interest-
ing electrochemical properties. The electron current through the
nanotube is based on ballistic conductivity, so the measured mean
free-path results to be two orders of magnitude higher than the best
macroscale conductor [26]. Electron transfer depends on surface
conditions: many works have been published regarding emission
properties of tips and walls of CNT [7], [29] to explain their high
rate. Moreover, they have been largely reported for the absorption
of proteins onto their walls, resulting in an excellent immobiliza-
tion method [4]. Surface modification by using carbon nanotubes
can be accomplished in different manner and for several purposes.
Directly growing of aligned carbon nanotubes have been proposed
on different substrates [15]. Another way to obtain aligned CNT
is by self-assembly: surfaces are generally modified with thiols or
other functional groups to link nanotubes [40]. Carbon nanotubes
can be also randomly dispersed on the electrode surface and many
efforts have been addressed to find the right solvent to disperse
CNT. Wang et al. showed that well-dispersed CNT solution can
be achieved by adding Nafion [54]. Carbon nanotubes can be used
as a forest of nanomaterials, patterned arrays or as single-sensors.
Nanowires and carbon nanotubes can be used to replace the chan-
nel in field-effect-transistor for biosensing purposes . As in the case
of electrochemical biosensors, biological sensing elements can be
adsorbed on NW or CNT surface and modify the conductivity of
the channel [52].
2.5 Electrode technology
Disposable biosensors are by far the most common tool sold in
the market. They avoid common drawbacks like cleaning process,
sterilization procedures, and contamination. On the other hand,
fully-implanted monitoring is not possible with disposable elec-
trodes, hampering the development of definitive solutions for the
treatment of diabetes. Biosensor integration is definitely needed for
such applications. Electrochemical-based sensing is the most suit-
able approach for the development of integrated biosensors. Am-
perometric, potentiometric, and impedimetric detection can be eas-
ily achieved with CMOS circuits next to the transducer. CMOS
technology brings some interesting advantages, especially for elec-
trochemical biosensors, where the signals are weak while the noise
is quite high. Signals involved in such measurements are often ana-
log, so the integration of analog-to-digital converters is required as
well. CMOS circuits are typically covered with one or more pas-
sivation layers, to isolate the chip from the outside and from con-
taminants. CMOS applied in biology are much more subject to
contamination and the wet environment does not guarantee proper
working conditions. So, integrated biosensors need hybrid solu-
tions. A really interesting and innovative solution for integrated
biosensors was proposed by Guiducci et al. [17]: they propose a 3-
D integrated system with vertically stacked layers and thru-silicon
vias among the different layers. This solution treats each layer with
different technologies, particulary suitable for the layer in contact
with the biological environment. The authors propose a disposable
biolayer, which is not suitable for fully-implanted devices, but can
represent a step towards the development of permanent systems.
Instead, the other layers designed for the readout, the transmission,
the power supply, and the post-processing are permanent.
3. CNT-BASED BIOSENSOR
In the present section we describe one possible strategy to de-
velop a platform of biosensors with the perspective to integrate the
electrodes and the electronics in an unique device. Following the
classification presented in Section 2, our biosensor can be described
as following:
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• Target: molecules, drugs
• Sensing element: enzymes
• Transduction mechanism: electrochemical (amperometric)
• Nanotechnology-based: carbon nanotubes
• Electrode type: disposable, integrated
Afterwards, we compare the performance of our developed biosen-
sors with others found in literature. We will focus on enzyme-based
electrochemical biosensors with similar modification of the elec-
trode surface by using CNT and functionalization with the same
type of protein.
3.1 Sensor description
Some biosensors are developed by using carbon paste screen-
printed electrodes (SPE) (Dropsens, Spain) as disposable electrodes.
The SPE consist of graphite working and counter electrodes, and
Ag reference electrode. Working electrode has an area equal to
13 mm2. Other molecules are detected by using a microfabricated
chip, consisting of five Au microelectrodes, Au counter electrode,
and Pt reference electrode. Each working electrode presents an area
equal to 0.25 mm2. Microfabrication details are described in [3].
All the electrode surfaces are modified with multi-walled carbon
nanotubes (MWCNT - diameter 10 nm, length 1-2 µm - Dropsens,
Spain) and functionalized with the enzyme-probe. Two families of
enzymes are used for the experiments: oxidases are used for the de-
tection of glucose, lactate, and glutamate, while cytochrome P450
(CYP) is used for arachidonic acid, ifosfamide, cyclophosphamide
(CP), and Ftorafur R©. Oxidase-based detection is investigated by
chronoamperometry with microfabricated Au electrodes and a drop
cast solution of MWCNT dispersed in Nafion 0.5%. The working
electrode potential is set at +650 mV and the current variation is
recorded, since it is proportional to the target concentration. CYP-
based sensing, instead, is carried out on screen-printed electrodes
modified with MWCNT dispersed in chloroform. A linear-sweep
potential is applied forward and backward within a certain poten-
tial window, while continuously monitoring the current. The hys-
teresis plot gives qualitative and quantitative information about the
detected target. In particular, the peak hight is proportional to drug
concentration and calibration curves can be plotted. Table 1 sum-
marizes the main characteristics of our developed biosensors.
3.2 Results of detection
Here following we will focus on the comparison between our
sensors and other similar biosensors found in literature. Table 2
summarizes the main features of the discussed biosensors, like the
sensitivity, the linear range, and the limit of detection.
3.2.1 Glucose biosensor
Glucose biosensors have been extensively investigated. Exam-
ples regarding diverse surface modification and functionalization
are largely reported in literature. Focusing on CNT-based biosen-
sors using glucose oxidase (GOD) as sensing element, our biosen-
sor shows the best performance for both sensitivity and limit of
detection compared to similar sensors reported in literature. We
achieve a sensitivity of 55.5 µA mM−1 cm−2 in a range from 0
to 1 mM, with a detection limit of 2 µM. Wang et al. [55] evapo-
rated a thin Au film onto grown MWCNT and they drop cast GOD
on top of the nanotubes, showing a sensitivity of 14.2 µA mM−1
cm−2. Another approach can be to mix CNT and GOD in the same
solution, with the addition of Nafion to increase the solubility of
nanotubes. Tsai et al. proposed this approach in [49], where they
Table 1: Features of different metabolite biosensors.
Target Probe Technique
GLUCOSE Glucose oxidase
ChronoamperometryLACTATE Lactate oxidase
GLUTAMATE Glutamate oxidase
ARACHIDONIC ACID custom-CYP
Cyclic voltammetry
FTORAFUR R© CYP1A2
CYCLOPHOSPHAMIDE CYP2B6
IFOSFAMIDE CYP3A4
drop cast the mixed solution on glassy carbon electrodes. In a linear
range from 0.025 to 2 mM, they got a sensitivity of 4.7 µA mM−1
cm−2. Regarding sensitivity, quite similar results were shown by
Ryu et al.: CNT forme a network on the electrode (defined mat)
and GOD is covalently bound to the nanotubes [42]. The highest
result in terms of sensitivity was presented in [18], showing 23.5
µA mM−1 cm−2 for MWCNT-based sensor with butyric acid (BA)
functionalization and GOD immobilization.
3.2.2 Lactate biosensor
Lactate biosensors have been less studied compared to glucose
biosensors, but there have been proposed diverse modification and
functionalization, as well. Our sensor shows a sensitivity of 25.0
µA mM−1 cm−2 within a range from 0 to 1 mmM, and a detec-
tion limit of 11 µM. Goran et al. [16] drop cast successively N-
doped CNT, LOD, and modified-Nafion onto glassy carbon elec-
trode. They obtained higher sensitivity than us, because carbon
electrode has better performance than metallic electrodes for the
detection of H2O2. In fact, we have already showed similar sen-
sitivity as [16] in our previous work by using carbon paste SPE
[5]. However, the linear range is very narrow (from 0.014 to 0.325
mM), which cannot fit with physiological lactate concentration.
CNT can be also incorporated with mineral oil to form a paste
and used as electrodes [41]. However, the resulting sensitivity is
quite low, 0.204 µA mM−1 cm−2, in an extended range from 0 to
7 mM. MWCNT have been also incorporated into sol-gel film to
form a further matrix for the immobilization of the enzyme. Huang
et al. deposited the obtained matrix onto glassy carbon electrode,
but they still showed a sensitivity ten times lower that our results
[19]. In the last example, the authors used titanate instead of car-
bon nanotubes [57]. The obtained sensitivity is much lower than
the previous case, suggesting that carbon gives better performance
not only for the nanoscale structure, but also for the material itself.
3.2.3 Glutamate biosensor
Glutamate is a neurotransmitter and its monitoring can be crucial
for neurochemical experiments. Lots of microsensors have been
proposed to be implanted in the brain and most of them are not
based on carbon nanotubes. Pan et al., for example, covered a Pt
electrode with Nafion matrix to entrap glutamate oxidase. The de-
tection was carried out in a really narrow range within 1 and 13
µM, obtaining a sensitivity of 16.1 µA mM−1 cm−2. Alternatively
to Nafion immobilization, Zhang [59] described the entrapment of
GlOD in chitosan, with a sensitivity of 85 µA mM−1 cm−2 within
0 and 200 µM. Similar linear range was also explored by Ammam
et al. [1]. Differently, they used MWCNT and polyurethane (PU)
onto Pt electrodes to increase the sensitivity (384 µA mM−1 cm−2)
and GlOD was dispersed in polypirrole (PP). All the previously de-
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Table 2: Comparison of electrochemical enzyme-based biosensors.
Modification Sensitivity Linear range Limit of detection
GLUCOSE
CNT mat + GOD [42] 4.05 µA mM−1 cm−2 0.2 - 2.18 mM –
MWCNT/Nafion + GOD [49] 4.7 µA mM−1 cm−2 0.025 - 2 mM 4 µM
MWCNT + GOD [55] 14.2 µA mM−1 cm−2 0.05 - 13 mM 10 µM
MWCNT-BA + GOD [18] 23.5 µA mM−1 cm−2 0.01 - 2.5 mM 10 µM
MWCNT/Nafion + GOD 55.5 µA mM−1 cm−2 0 - 1 mM 2 µM
LACTATE
MWCNT/mineral oil + LOD [41] 0.204 µA mM−1 cm−2 0 - 7 mM 300 µM
Titanate NT + LOD [57] 0.24 µA mM−1 cm−2 0.5 - 14 mM 200 µM
MWCNT + sol-gel/LOD [19] 2.1 µA mM−1 cm−2 0.3 - 1.5 mM 0.3 µM
N-doped CNT/Nafion + LOD [16] 40.0 µA mM−1 cm−2 0.014 - 0.325 mM 4 µM
MWCNT/Nafion + LOD 25.0 µA mM−1 cm−2 0 - 1 mM 11 µM
GLUTAMATE
Nafion + GlOD [33] 16.1 µA mM−1 cm−2 0.001 - 0.013 mM 0.3 µM
Chit + GlOD [59] 85.0 µA mM−1 cm−2 0 - 0.2 mM 0.1 µM
PU/MWCNT + GlOD/PP [1] 384 µA mM−1 cm−2 0 - 0.14 mM 0.3 µM
MWCNT/Nafion + GlOD 0.9 µA mM−1 cm−2 0 - 2 mM 78 µM
ARACHIDONIC ACID MWCNT + CYP 1140.0 µA mM−1 cm−2 0 - 0.04 mM 0.4 µM
CYCLOPHOSPHAMIDE MWCNT + CYP 102.0 µA mM−1 cm−2 0 - 0.07 mM 2 µM
IFOSFAMIDE MWCNT + CYP 160.0 µA mM−1 cm−2 0 - 0.14 mM 2 µM
FTORAFUR R© MWCNT + CYP 883.0 µA mM−1 cm−2 0 - 0.008 mM 0.7 µM
scribed sensitivities are higher (up to three orders of magnitude)
than the one obtained by our biosensors. In fact, we achieve a sen-
sitivity of 0.9 µA mM−1 cm−2 and a detection limit of 78 µM. On
the other hand, we exploit a wider linear range (from 0 to 2 mM),
useful for some particular applications like cell culture monitoring.
3.2.4 CYP-based biosensor
Arachidonic acid is a fatty acid abundant in liver, brain, and mus-
cles. Its detection can be carried out by the isoform CYP102A1,
for example. We got a customized CYP isoform from EMPA (St.
Gallen, Switzerland) for the detection of fatty acids. Carbon paste
SPE are modified as described previously by using MWCNT and
the detection is performed by applying cyclic voltammetry. The de-
veloped biosensor shows a sensitivity of 1140.0 µA mM−1 cm−2
within a linear range from 0 to 40 µM, and a detection limit of
0.4 µM. In literature, the detection of such compound is typically
optical, as presented by Giovannozzi et al. [14], and noone has de-
scribed yet electrochemical detection by using CYP450.
Drugs can be detected using different isoforms of cytochrome P450.
Here we present the results obtained from the detection of three
drugs. Cyclophosphamide and ifosfamide are two alkilating agents,
commonly used in anticancer treatments and as immunosuppres-
sant. The third drug is a chemotherapeutic prodrug. Among these
three drugs, CP is the only one for which electrochemical biosen-
sors were previously developed. They are typically DNA-based and
the signal variation is recorded when the CP interacts with DNA
strands under differential pulse voltammetry [32]. We develop an
enzyme-based electrochemical biosensor by using three different
isoforms of CYP450 for the detection of such compounds. For
CP we obtained a sensitivity of 102.0 µA mM−1 cm−2 in a lin-
ear range within 0 and 70 µM and a detection limit of 2 µM. For
ifosfamide we got a sensitivity of 160.0 µA mM−1 cm−2 within
a range from 0 and 140 µM, with a detection limit of 2 µM. Fi-
nally, Ftorafur R© is detected with a sensitivity of 883.0 µA mM−1
cm−2 in a linear range within 0 and 8 µM and a detection limit
of 0.7 µM. In conclusion, it is the first time that electrochemical
biosensors based on MWCNT and CYP are used for the detection
of the aforementioned compounds. These results are really promis-
ing for the development of integrated biosensors for monitoring of
drug mixture in the blood, paving the way to innovative tools for
personalized therapy.
4. CONCLUSIONS AND PERSPECTIVES
The aim of the present work is to give an overview on biosens-
ing strategies and developed devices. In particular, our attention
is focused on nanotechnology-based biosensors and the possibil-
ity of their integration in more complex systems. Then, we pro-
posed one possible strategy to develop biosensors for the detection
of some biomolecules and drugs, showing that surface modifica-
tion of the electrode with nanostructures can enhance the perfor-
mance in biosensing. The detection of multiple endogenous and
exogenous compounds is essential for personalized therapy. All
the presented results are really promising in the perspective to de-
velop point-of-care devices. The variety of individual responses
to the same treatment requires potent tools for the monitoring of
metabolic mechanisms, to optimize therapy management and effi-
cacy. Enhanced sensitivities and lower detection limit can satisfy
these demands, as showed by our developed biosensors.
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